The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.

Launched by NATIONAL INSTITUTE OF BLOOD AND MARROW TRANSPLANT (NIBMT), PAKISTAN · Jan 1, 2025

Keywords

ClinConnect Summary

1. Introduction:

Androgenetic Alopecia (AGA) is a common form of hair loss affecting both men and women, characterized by the miniaturization of hair follicles due to the influence of a variety of factors including androgens and genetics. AGA affects a sizeable portion of the population worldwide, affecting males and females both.1 While many accept it as a normal physiological process of ageing, for others it causes remarkable concern and worry, especially pertaining to personal appearance and self-confidence. So much so leading to body image issues and even psychological disorders1,2,...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male patients with AGA between age 25 to 59 years of age
• • Clinical presentation consistent with Hamilton Norwood criteria grade ll to Vl
• • Not currently receiving antiandrogens or minoxidil therapy.
• Exclusion Criteria:
• • Patients with hair loss other than AGA
• • Patients receiving 5-alpha reductase inhibitor or minoxidil therapy
• • Patients who received PRP for at least 6 months prior to enrollment
• • History of hypertrophic scars or bleeding disorders
• • History of treatment with hyper or hypothyroidism